QTTB catalyst calendar

Q32 Bio Inc.

Upcoming catalysts
1
Cash runway
50.3 months
Cash & investments
$106M

Q32 Bio Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.

Cash runway is approximately 50.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —

Track QTTB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open QTTB in the tracker

Recent history

DateEventTypePhase
September 30, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 14, 2026 8-K filed: Reg FD disclosure, Other event Filing —
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 15, 2026 8-K filed: Material agreement Corporate —
July 13, 2026 8-K filed: Reg FD disclosure, Other event Filing —
July 13, 2026 8-K filed: Other event Filing —
June 15, 2026 A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) Trial Milestone Phase 2
May 27, 2026 8-K filed: Material agreement, Other event Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 24, 2026 8-K filed: Other event Filing —
March 27, 2026 8-K filed: Material agreement Corporate —
March 10, 2026 Quarterly results filed (8-K) Earnings —
February 17, 2026 8-K filed: Material agreement, Other event Corporate —
December 19, 2025 8-K filed: Leadership change Corporate —
December 1, 2025 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure, Other event Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
October 21, 2025 8-K filed: Other event Filing —
August 6, 2025 Quarterly results filed (8-K) Earnings —
June 25, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 23, 2025 8-K filed: Listing / standard notice Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 25, 2025 8-K filed: Leadership change Corporate —
December 15, 2024 Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Trial Milestone Phase 2
January 12, 2022 Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.